Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2015-04-19 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2015年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2015 年第一季度报告" which translates to "2015 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, income statements, cash flow data, shareholder information, and management commentary on financial performance and changes. The report is explicitly stated as "未经审计" (unaudited) and covers a period shorter than a full fiscal year (the first quarter of 2015). The content includes comprehensive financial statements and analysis typical of an interim or quarterly report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2015
2015-04-19 Chinese
股权激励计划当期购买股份开始公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the commencement of share repurchase under its equity incentive plan. It details the purpose, basis, method, price, quantity, funding source, and expected impact of the share buyback. The text includes specific figures on the repurchase amount, timeline, and shares involved. It is not a financial report, earnings release, or management discussion but a notification about the company's share repurchase activity related to an employee incentive plan. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length is under 5,000 characters and contains substantive details about the repurchase, so it is not merely an announcement of a report (RPA) or a regulatory filing (RNS). Therefore, the correct classification is POS with high confidence.
2015-04-19 Chinese
七届三十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 38th meeting of the 7th board, including approval of stock incentive plans, stock repurchase proposals, and cash performance rewards for executives. The document is an official announcement of board decisions rather than a full management report or financial statement. It does not contain financial data or detailed management discussion but focuses on board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear identification of board meeting resolutions and voting results.
2015-04-19 Chinese
关于2014年年报事后审核意见回复的公告
Audit Report / Information Classification · 95% confidence The document is a detailed response to post-audit comments on the 2014 annual report of Kunming Pharmaceutical Group Co., Ltd. It includes extensive financial data, operational details, product sales, R&D expenditures, and corrections related to the 2014 annual report. The document references the 2014 annual report multiple times and provides clarifications and supplementary information requested by the Shanghai Stock Exchange. The length of the document (over 11,000 characters) and the detailed financial and operational data indicate it is not a brief announcement but a substantive report. The content aligns with an Annual Report (10-K) or a related detailed financial report. However, since it is a reply to audit comments on the annual report and includes detailed financial and operational data, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports, applied accounting principles, and responses to regulatory reviews excluding the full annual report itself. Therefore, the document is classified as an Audit Report / Information (AR). FY 2014
2015-04-10 Chinese
2014年度审计报告（修订版）
Audit Report / Information Classification · 95% confidence The document is titled as the 2014年度财务报表附注 (2014 Annual Financial Statement Notes) of Kunming Pharmaceutical Group Co., Ltd. It includes an audit report section with a registration number from a Chinese audit firm, detailed descriptions of accounting policies, consolidation scope, and financial statement preparation methods. The content is extensive (15,000 characters) and contains detailed financial and accounting information, including audit responsibilities and accounting standards applied. This matches the characteristics of an Audit Report / Information filing, which includes standalone audit reports and applied accounting principles, distinct from the full Annual Report. There is no indication that this is a full Annual Report (10-K) or just an announcement. Therefore, the document is best classified as an Audit Report / Information (AR). FY 2014
2015-04-10 Chinese
2014年年度报告(修订版)
Annual Report Classification · 100% confidence The document is titled '2014 年年度报告' which translates to '2014 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data and indicators, board of directors report, risk disclosures, financial statements, and notes. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes audited financial data, management discussion and analysis, and comprehensive financial and operational information for the fiscal year 2014. The presence of an audit opinion from an accounting firm is noted but the document itself is not just an audit report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2014
2015-04-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.